Navigation Links
New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
Date:5/5/2009

TOKYO and INDIANAPOLIS, Ind., May 5 /PRNewswire-FirstCall/ -- A new substudy from 1,466 patients from the Phase III TRITON-TIMI 38 clinical trial showed that patients who took prasugrel and had a reduced function of the CYP2C19 gene did not have an increased risk of cardiovascular death, heart attack or stroke compared with those patients who had normal function. The substudy results were published online in Circulation on May 4, 2009(1).

Prasugrel is a "prodrug" that requires the use of cytochrome P450 (CYP) enzymes to convert the drug into the active metabolite. Approximately 30 percent of Caucasians and 60 percent of Asians have reduced function in the CYP2C19 gene, which is part of the CYP system and encodes the enzymes that are responsible for converting prasugrel into its active form(2).

In the substudy, researchers examined how variation in cytochrome P450 (CYP) genes affected the response to prasugrel. In prasugrel-treated patients with acute coronary syndromes (ACS) who underwent an artery-opening procedure known as percutaneous coronary intervention (PCI), the incidence of the combined endpoint of cardiovascular death, heart attack or stroke was 8.5 percent (N=407) in those who carried at least one variant in the CYP2C19 gene that reduced its function versus 9.8 percent (N=1048) in patients without a genetic variant (P=0.27). In addition, the rate of stent thrombosis in carriers of the reduced-function variant in the CYP2C19 gene compared with non-carriers treated with prasugrel was 0.5 percent vs. 1.0 percent, respectively (P=0.48). The results also showed that rates on non-CABG-related TIMI major or minor bleeding did not significantly differ by genetic variant among those treated with prasugrel.

"It is well documented in the medical literature that particular genetic variants in the CYP2C19 gene are associated with an increased risk of cardiovascular outcomes in patients treated with c
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... sale to Galderma of all rights to Restylane, Perlane, ... for $1.4 billion in cash, pursuant to the previously ... acquisition of Galderma. "We are pleased ... company that is firmly committed to the aesthetic dermatology ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 /PRNewswire/ ... three-quarters of surveyed infectious disease (ID) specialists are ... Medicines Company,s Orbactiv (oritavancin) for use as OPAT, ... to prescribe these agents to their hospital inpatients. ... percent) of OPAT patients are initiated on OPAT ...
(Date:7/10/2014)... CVS Caremark Corporation (NYSE: CVS ) ... quarterly dividend of $0.275 (27.5 cents) per share on the ... 2014, to holders of record on July 21, 2014. ... dedicated to helping people on their path to better health ... United States . Through the company,s more than 7,600 ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... AlloSource, one of the nation,s largest non-profit providers of ... procedures and the world,s largest processor of live cellular bone ... judged by the ColoradoBiz Top Company awards program. ... for the past decade, AlloSource saved and enhanced the lives ...
... Health Organization has issued a warning to medical travelers: ... heels of a growing threat of an antibiotic-resistant superbug, ... the region in India where it was discovered. "Many ... or knee replacements, ACL surgeries, root canals and spinal ...
Cached Medicine Technology:AlloSource Named Colorado's Top Healthcare Company 2New York Plastic Surgery News: Medical Tourists Beware of Drug-Resistant Superbug NDM-1 2
(Date:7/10/2014)... New York, US (PRWEB) July 10, 2014 ... . , Merrill DataSite recently streamed the live webinar ... featuring a discussion from a group of several M&A ... are seeing in the broader energy transaction marketplace. These ... hot and how the deal market in this sector ...
(Date:7/10/2014)... A Forever Recovery , an ... off to a great start and gives them a ... launched a new Eating Disorders section of its website ... , Different types of eating disorders ... Disorders (DSM-IV), including anorexia nervosa, bulimia nervosa, and EDNOS ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Nature, not nurture, ... of individual chimpanzees, a new study finds. "As ... comes to cognitive [thinking] abilities in chimpanzees," William Hopkins ... said in a news release from the journal ... insight into the evolution of intelligence in humans, Hopkins, ...
(Date:7/10/2014)... 10, 2014 (HealthDay News) -- Men who have a ... cancer, a new study suggests. But the risk ... not involved with the study said more research is ... accurate. For the study, Harvard researchers analyzed data ... for 24 years, starting in 1986. During that time, ...
(Date:7/10/2014)... aggression, who research issues ranging from child abuse to ... of the International Society for Research on Aggression (ISRA) ... State University is hosting the prestigious world meeting, which ... "We are excited to be bringing together leading scholars ... produce fresh ideas about the causes, consequences and solutions ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3
... Mothers who are depressed respond differently to their crying ... according to brain scans at the University of Oregon, ... in non-depressed moms. An infant crying is normal, ... says Jennifer C. Ablow, professor of psychology. For years, ...
... This release is available in Spanish . ... and cooperators have confirmed what many pollen-sensitive people already suspected: ... longer and ends later. Ragweed pollen in some ... almost a month longer than it did in 1995, and ...
... , TUESDAY, Feb. 22 (HealthDay News) -- Despite suggestions ... skin condition known as atopic eczema, a new British ... to relieve sufferers. "Although the outcome is disappointing ... eczema, the outcome of the trial is very clear," ...
... HealthDay Reporter , TUESDAY, Feb. 22 (HealthDay News) -- ... increased risk of ischemic stroke, which typically occurs when blood ... fatty deposits within blood vessels, a new Danish study contends. ... pronounced for triglyceride fats than it is for cholesterol, even ...
... researcher believes there could be a new drug compound ... also help with controlling cholesterol. Salman Hyder, the ... biomedical sciences in the College of Veterinary Medicine and ... discovered that a small molecule, Ro 48-8071, initially developed ...
... leap forward in understanding Huntington,s disease may give patients ... cells and post-mortem brain tissue of Huntington,s disease patients ... that causes brain nerve cells to die. Toning down ... the chain reaction and kept those cells alive, according ...
Cached Medicine News:Health News:Crying baby draws blunted response in depressed mom's brain 2Health News:Crying baby draws blunted response in depressed mom's brain 3Health News:USDA study confirms links between longer ragweed season and climate change 2Health News:Softening Water Does Not Seem to Ease Eczema 2Health News:High Triglyceride Levels Linked to Increased Stroke Risk: Study 2Health News:High Triglyceride Levels Linked to Increased Stroke Risk: Study 3Health News:Compound used to block cholesterol could also kill breast cancer, MU researcher finds 2Health News:Huntington's disease breakthrough equals hope for patients 2
... interoperative placement to stent the ... and continent urinary diversions. Supplied ... for one-time use. CAUTION: Periodic ... not remain indwelling more than ...
... a device that provides effective cutting and simultaneous ... to provide the urologist with the same touch ... the approximate speed and the same ease of ... but with a 45% greater zone of ...
Used for stone manipulation and removal in the renal pelvis under direct vision. Supplied sterile in peel-open packages. Intended for one-time use....
Used for stone manipulation and removal in the renal pelvis under direct vision. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: